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Abstract 
In 2014 the contribution of aquaculture to supply food for human consumption overtook wild-
caught fish for the first time. Despite improvements in the aquaculture industry, it has been 
estimated that as much as 10% of all cultured aquatic animals are lost because of infectious 
diseases, amounting to >10 billion USD in losses annually on a global scale. 
Vaccination to prevent disease is used routinely in finfish aquaculture, especially for 
Atlantic salmon (Salmo salar), while in a limited capacity (or not at all) in many other fish 
species due to lack of vaccines, poor performance or cost. There has, nevertheless, been 
impressive progress in fish vaccine development over the last 4 decades with 24 licenced fish 
vaccines now commercially available for use in a variety of fish species. These comprise whole 
killed, peptide subunit, recombinant protein, DNA and live attenuated vaccines.  
Challenges do, however, still exist as the majority of commercial vaccines are killed 
whole cell pathogen preparations administered by intraperitoneal injection. This may not be 
the optimal route to deliver some vaccines, but lack of effective adjuvants and basic knowledge 
on immune response has hindered progress in the development of mucosal vaccines. The cost 
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of injecting fish may also be prohibitive in some countries leading to disease treatment (e.g. 
with antibiotics) rather than using preventative measures. It is important that these issues are 
addressed as the industry continues to grow globally.  
Exciting opportunities exist for rapid development of fish vaccines in the future, with 
continued reduction in cost of technologies (e.g. of whole genome sequencing), regulations 
changing (e.g. DNA vaccines can now authorised in Europe), the introduction of novel antigen 
expression and delivery systems (such as virus-like particles, VLPs), development of novel 
adjuvants and advancements in the elucidation of basic mechanisms of mucosal immunity. 
Development of effective mucosal vaccines and optimisation of their delivery will facilitate 
novel vaccine development, and enable the aquaculture industries in LMIC to use vaccination 
routinely in the future. In addition, effective use of emergency (autogenous) vaccines will assist 
in tackling emerging disease challenges. 
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Aquaculture contributes ~80 million Tonnes of aquatic animals with a value of US$ 232 billion 
and represents the fastest growing animal production sector in the world, with twenty-seven 
finfish species contributing 90 per cent of global aquatic animal production [1]. Atlantic salmon 
(Salmo salar) is listed as the number one fish species in terms of economic value while Carp 
species are top with regards to volume. Aquaculture is not only an important source of income, 
but contribution to food security and social development of many countries. The main 
constraint to aquaculture globally, however, is disease with an estimate that 10% of all cultured 
aquatic animals are lost because of infectious diseases, amounting to >10 billion USD in losses 
annually on a global scale [2].  
Vaccines are recognised as important tools for the prevention and control of fish 
diseases and are used routinely in aquaculture, especially for Atlantic salmon (Salmo salar), 
while in a limited capacity (or not at all) in other fish species due to lack of vaccines, poor 
performance or cost. Vaccination has been recognised as an essential route to the reduction in 
use of antibiotics within the aquaculture industry in the UK and Norway [3,4] although overuse 
or inappropriate use has been reported in various fish species in other regions of the world 
[5,6,7]. 
 
Progress in Vaccine Development 
History of fish vaccines: Atlantic salmon and rainbow trout aquaculture in the UK, Norway 
and USA expanded in the 1980’s, accompanied by a rapid increase in disease, particularly with 
bacterial pathogens such are Vibrio species, Yersinia ruckeri and Aeromonas salmonicida. As 
a consequence large quantities of antibiotics were used and concerns grew with regards to 
antibiotic resistance. This stimulated the development of fish vaccines and led to the first 
commercially available fish vaccines against Vibriosis, Enteric Red Mouth (ERM) and 
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Furunculosis. The first vaccine for aquaculture was actually the ERM vaccine for salmonid fish 
licensed in 1976 in the USA [8]. Currently 19 major companies market fish vaccines globally 
and many small companies also exist [9]. 
 
Commercial vaccines: The number of commercial vaccines available for use in fish have 
expanded, from 2 in the 1980s to 24 currently [10,11], with one vaccine also available for 
lobsters [2]. Fish vaccines are available for a wide range of species [2,11,12], including Atlantic 
salmon, Rainbow trout, sea bass (Dicentrarchus labrax) and sea bream (Sparus aurata), tilapia 
(Oreochromis niloticus/mossambicus), amberjack (Seriola dumerili) and yellowtail (Seriola 
quinqueradiata) in Japan, catfish (Ictalurus punctatus) and Vietnamese catfish 
(Pangasionodon hypophthalmus). Most are formalin killed whole cell vaccines although live 
attenuated vaccines are licensed in the USA for use in catfish [13]. A DNA vaccine against 
infectious haematopoietic necrosis (IHN) is licensed in Canada for use in Atlantic salmon [14] 
and a subunit vaccine (peptide; VP2) is used in Norway (against infectious pancreatic necrosis 
virus, IPNV) and a recombinant vaccine against infectious salmon anaemia virus, ISAV is used 
in Chile. Many Atlantic salmon vaccines are multivalent and there is a trend towards micro-
dose application (i.e. 50ul versus 100ul). Although carp and tilapia are well established cultured 
species, there are few vaccines available for these species and the number of commercial 
vaccines available for trout has decreased, with the monovalent furunculosis vaccine being 
taken off the market.  
There are a number of important considerations for the use of commercial vaccines in 
fish, including fish species, status of the immune system, production cycle and life history, 
when disease occurs, farming technology (handling, mechanisation etc), environment (e.g. 
temperature, salinity), stress factors, nutrition and cost benefits. Guidelines on the use of fish 
vaccines are provided by Responsible Use of Medicines in Agriculture Alliance [15]. The 
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majority of commercial vaccines include adjuvants and are administered by intraperitoneal 
injection [11]. 
 
Fish species and diseases where vaccines are needed for aquaculture: Bacterial disease still 
presents major challenges for rainbow trout, carp, tilapia and catfish aquaculture. In addition, 
there are few effective vaccines against viral diseases and these pose significant problem in 
salmonid and marine finfish [16]. Parasite diseases, in particular the Ectoparasites, 
Lepeophtheirus salmonis (sealice) and Paramoeba perurans (which causes amoebic gill 
disease, AGD), currently represent significant disease threats for the Atlantic salmon industry 
and no commercial vaccines exist for these, nor for fungi or fungi-like organisms. In addition, 
there are no vaccines for opportunistic facultative parasites (e.g. Saprolegnia and 
Aphanomyces) that are problematic in salmonid aquaculture and tropical fish species (many 
freshwater and brackish species in the Asia-Pacific region and Australia), respectively.  
 
Challenges in Fish Vaccine Development 
The most crucial step in developing an effective vaccine is identification of ‘potentially’ 
protective antigens and confirming their protective response in the host species against the 
pathogen of interest. The approach taken depends on pathogen type, fish species, 
administration method, availability of reagents, and whether a challenge model has been 
developed to efficacy test the vaccine candidates. Identifying protective antigens is not easy 
and requires a variety of approaches.  
The majority of commercial fish vaccines are killed whole cell pathogens preparations 
and are administered by intraperitoneal injection. Using whole pathogens in a vaccine can pose 
problems if the pathogen species is very heterogeneous, when they are difficult or expensive 
to culture, if some epitopes immunosuppress, and in general for intracellular or complex 
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pathogens (e.g. parasites). In addition, injection may not be the optimal route to deliver some 
vaccines and mucosal delivery may be required for effective protection, however, lack of 
adjuvants and insufficient basic knowledge has held back progress in the development of 
mucosal vaccines. The cost of injecting fish may also be prohibitive in some countries, with 
costs of hiring staff to inject fish and convenience playing a large role in available commercial 
fish vaccines in Low to Middle Income (LMIC) counties. 
 
Challenge models: Testing the efficacy of vaccines requires standardised in vivo disease 
challenge models that closely mimic the natural exposure route to the pathogen. Although more 
difficult to control and standardise than injection challenge methods, bath and co-habitation 
challenges best fulfil the requirement of natural exposure. Pathogen load (measured by qPCR) 
and immunological markers of protection (analysed by immunohistochemistry and/or gene 
expression) can be used as proxies to test the efficacy of vaccines if no experimental disease 
challenge method is available or may not be reproducible; field trials can be performed is 
certain circumstances. For example, Rainbow Trout Fry Syndrome (RTFS) caused by the gram 
negative bacterium, Flavobacterium psychrophilum, is very difficult to induce experimentally 
by bath or co-habitation challenge unless scarification or stress is used [17,18]. Although 
intramuscular injection induces disease, his is not an appropriate challenge method to test a 
mucosal vaccine (e.g. dip immersion) administered to fry. Pre-treatment of fish with low levels 
of hydrogen peroxide is required for the challenge to succeed but the even with this treatment 
the level of infection is not sufficient to fully test vaccine efficacy [19,20,21] so field trials are 
planned. 
 
Fish Species and Diseases:  The diversity of fish species itself poses a challenge in vaccine 
development as we still do not fully understand the fish immune system and each fish species 
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requires reagents/primers to elucidate host pathogen interactions. In addition, although 
injection is commonly used for Atlantic salmon, this may not be viable for some species e.g. 
tilapia and Pangasius. 
 
Administration methods: Optimal methods of vaccine administration still need to be 
determined. It may be that some novel vaccines being develop are protective, but current 
administration methods and vaccination strategies are not appropriate for optimal efficacy (e.g. 
may need prime/booster vaccination).  Fish have large mucosal surfaces (skin, gills, gut and 
nasal mucosae) and administration of vaccines via the mucosal route is also more practical and 
affordable for some sectors than injection. A limited number of mucosal (immersion and oral) 
vaccines are, however, commercially available. A number of challenges have hampered their 
development, including lack of correlates of protection, lack of optimisation of protective doses 
required, possibility of oral tolerance, the potential for denaturation of oral vaccines in the 
stomach, and the ability of antigens to cross mucosal barriers to gain access to antigen 
presenting cells (APCs) [22].   
 
Adjuvants: Adjuvants are included in injection vaccines but are limited for mucosal 
vaccination. Adjuvants are a group of structurally heterogeneous compounds that are capable 
of modulating the intrinsic immunogenicity of an antigen [23].  They have been classified 
according to the immune response they elicit, Signal 1 (presentation of antigen) or Signal 2 
facilitators (additional secondary signals) [24]. Both are required for activation of specific T 
and B lymphocytes [25]. Adjuvants have improved over recent years and a range of effective 
products (e.g. Montanides, classified as Signal 1 adjuvants) are available from SEPPIC for use 
with injection vaccines for fish. Signal 2 adjuvants, such as beta glucans, alums, saponins, poly 
I:C,  synthetic oligonucleotides, cytokines and flagellin, provide co-stimulatory signals during 
8 
 
antigen recognition, recently reviewed by Dalmo, Bogwald and Tafalla [26]. Recent work 
using a recombinant flagellin from the salmonid pathogen Yersinia ruckeri, showed it to be a 
potent activator of inflammatory cytokines, acute phase proteins and antimicrobial peptides in 
vitro and to be a more inflammatory activator than other bacterial PAMPs (LPS, peptidoglycan) 
[27].  In vivo studies revealed that it activated a variety of anti-microbial pathways with 
heightened expression of acute phase proteins, antimicrobial peptides and complement genes 
in multiple tissues. Trout liver in particular appeared responding to flagellin stimulation, with 
marked induction of IL-11, IL-23P19, IL-17C1, SAA, and cathelicidin-2. Overall this 
suggested that flagellin could be a potent immunostimulant and vaccine adjuvant for fish 
aquaculture [27]. Despite these exciting new findings there is currently a lack of effective 
commercial immersion adjuvants for use in fish. 
 
Immune response and markers of protection: It is important to be able measure the responses 
induced by vaccination in teleost fish to enable the development of new and evaluate existing 
vaccines. The adaptive immune response has the main role in providing protection following 
vaccination, mediated by T and B lymphocytes. There are gaps in knowledge, however, 
especially with correlates of protection for mucosal vaccines [22;47], although progress is 
being made on in this area. For example, protocols have been developed for isolation of GALT 
cells from salmonids and these have been shown to express a wide range of T-cell, B-cell and 
dendritic cell markers, and to be differentially responsive to a panel of PAMPS, cytokines and 
PHA [48]. Such information will assist in the development of oral vaccines. 
 
T cell response: Efficient antigen recognition and presentation are required for effective 
vaccination. Vaccine antigens are usually presented through MHC-11 molecules to T cells, 
while DNA vaccination is mediated through the MHC-1 route, although it should be noted that 
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both responses can be triggered simultaneously with one prevailing as the immune response 
develops, reviewed by Secombes and Belmonte [28]. This can be influenced with choice of 
adjuvant. Markers of protection for T cell responses still pose a challenge despite numerous 
studies on cytokine expression [28].  
 
B cell response: With regards to B cell responses, correlation with antibody production does 
not necessarily infer a protective response; passive immunisation can be used to demonstrate 
the protective effect of antibodies [28]. In fish, in contrast to mammals, there appears to be no 
increase in antibody level following booster vaccination and it is thought that more cells are 
actually produced during the memory response rather than an increase in antibody level. 
Numerous publications report increases in specific IgM following injection vaccinations, while 
IgT has been reported following immersion vaccination is some fish species. For example, 
immersion vaccination of rainbow trout with an RTFS vaccine resulted in an increase in IgT 
producing cells in the kidney [21]. Munang'andu, Mutoloki and Evensen [29] suggested that 
there is compartmentalisation in the physiological distribution of IgT and IgM in some mucosal 
organs, as demonstrated in the gills where IgT is mainly found on exterior surfaces of the gill 
lamellae [30,31] suggesting that this isotype may act as gatekeeper at pathogen portals of entry.  
In contrast, as IgM is mainly found in arterioles [30,31], Munang'andu, Mutoloki and Evensen 
[29] suggested that its role is a secondary defence strategy that would kick in when IgT on 
mucosal surfaces fails to prevent the penetration of pathogens into the systemic environment. 
 
Opportunities and Future Directions  
The genomes of a variety of fish species are now available. In addition, with the reduction in 
cost of technologies, such as the whole genome sequencing, the genomes for specific pathogens 
are regularly reported [32], enabling targeted vaccine design for heterogenous species. For 
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examples, Ngo and co-authors [33] characterised over 300 Flavobacterium psychrophilum 
species, mainly form the UK, and produced an effective tivalent whole cell vaccine. These 
results are also extremely important from an epidemiological point of view [32]. Sometimes it 
may not be possible to develop a whole cell vaccine as some epitopes may be 
immunosuppressive and therefore specific potential protective antigens need to be identified 
and vaccines produced, thereby eliminating unwanted epitopes. 
 
Identification of specific potential protective antigens: 
Reverse vaccinology is a genome based approach widely used to identify potential vaccine 
candidates for development of protein subunit vaccines. Protein sequences from the pathogen 
are screened and then potential vaccine candidates selected using software programmes. They 
may be selected on the basis of being known vaccine candidates for other pathogens, highly 
immunogenic proteins or other criteria. Recombinant subunit vaccines (or DNA vaccines) are 
then produced and efficacy tested in vivo. DNA vaccines are now authorised for use in Europe 
[49] and so many more will likely be developed in the future. 
 
mRNA vaccines: As an alternative to DNA vaccines, mRNA vaccination is now being used in 
clinical medicine. The technology was first introduced in 1990 but as there were concerns over 
stability, high innate immunogenicity and inefficient in vivo delivery it was not pursued at that 
time. Stability and delivery methods have been improved and the vaccines can be produced 
quickly and inexpensively [34]. Such vaccines have been used particularly for prophylactic and 
therapeutic applications in cancer, with clinical trials of mRNA vaccines for infectious disease 
still in their infancy. They have been shown to be safe in clinical trials for HIV, but although 
the vaccines elicit antigen specific CD4+ and CD8+ T cell immune responses, there was no 
reduction of viral load. Vaccination against rabies virus demonstrated that efficacy was highly 
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dependent on the dose and route of administration, with needle free administration superior to 
direct injection, reviewed by Pardi and co-aturhors [34]. 
 
Vaccine delivery using nanoparticles: Nano materials (<1000nm) such as virus-like particles 
(VLPs), liposomes, immunostimulating complexes (ISCOMs), polymeric, and non-degradable  
nanospheres have been reported to have potential as delivery vehicles for vaccine antigens; 
these stabilise vaccine antigens as well as acting as adjuvants [35]. They can drive the immune 
response in various directions and may be important for induction of protective responses. Such 
delivery systems are suitable for mucosal delivery of vaccines. Nanoparticles serve both as 
antigen delivery vehicles and to allow a sustained release of antigens, thus reducing the need 
for booster vaccinations [22,36,37,38,39]. Among the polymeric systems, poly D,L-lactide-co-
glycolic acid (PLGA) nanoparticles  have been widely used for the controlled delivery of 
peptides, synthetic proteins, and nucleic acids in humans [40] and have been tested in fish for 
the delivery of oral vaccines [36,37,38,39]. More recently VLPs have been tested in fish. These 
are considered a novel vaccine platform because they are not infectious and they induce 
neutralizing antibodies. Chien, Wu and Li [41] demonstrated that orange-spotted grouper NNV 
(OSGNNV) VLPs have potential as oral vaccines in grouper. The recombinant capsid proteins 
were produced in Escherichia coli and cell-free self-assembled into VLPs. Pichia pastoris can 
be used as an alternative expression system to E.coli and has been shown to be a good vehicle 
for oral antigen delivery. It can be used in non-encapsulated form for older fish or in bio-
encapsulated form for larval fish, while the yeast itself acts as an adjuvant [42]. 
 
Prime versus prime booster vaccination: Injection vaccines administered with adjuvants are 
generally only injected once, eliciting a long lived response (up to one year). Immersion 
vaccination performed without adjuvant, on the other hand, will be short lived and a booster 
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vaccination will normally be required. Fish vaccines so far, have not, provided sterile immunity 
and perhaps stimulating both mucosal and systemic immunity is required to achieve this [22]. 
This could be achieved by an early immersion vaccination then IP booster vaccination, or IP 
booster vaccination followed by oral booster vaccination. 
 
Live attenuated vaccines: The first vaccine to protect humans against smallpox was a live 
vaccine in the 1770s [43]. Such vaccines have the advantage that they stimulate both humoral 
and cellular activity, but due to safety concerns they are not allowed to be used in European 
aquaculture. This is because there is a risk that live attenuated isolates may revert to virulent 
forms. Traditionally attenuation was achieved by passaging the pathogen in vitro multiple times 
leading random mutations. Molecular methods can now be used to target specific genes and 
produce genetically modified the pathogens, but these are classified as GMOs and regulations 
for their use are very strict in aquaculture, more so in fact that traditional live vaccines [9]. It 
has been reported that defined genetic modifications permit better control and safety than 
random mutations in live bacterial vaccines [44], so perhaps these types of vaccine will be 
permitted in the future. 
 
Autogenous vaccines: It is expensive and time consuming to develop commercial vaccines and 
there are a huge variety of fish species being cultured that are susceptible to a various diseases. 
It is therefore not realistic to develop licenced vaccines against all fish pathogens, and this may 
in fact not be possible for some particular pathogens due to a variety of reasons. Emergency, 
or autogenous vaccines, can be a useful alternative. For example, cleanerfish (e.g. Ballan 
wrasse, Labrus bergylta and lumpsucker, Cyclopterus lumpus) that are being used to control 
sealice in Norway and the UK are affected by disease. The pathogens isolated from Ballan 
wrasse appear to vary from site to site and autogenous vaccine against bacterial pathogens have 
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been effective in controlling at least some of these diseases, such as atypical Aeromonas 
salmonicida when administered by injection [45]. Nevertheless, diseases are still problematic 
in fry and there is a lack of knowledge of when this species becomes immunocompetent and 
can be successfully vaccinated by immersion vaccination, if at all. Recently, it has been 
reported that natural IgM is at very high levels in the intestine of Ballan wrasse and it was 
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